Thomas Steyer’s Spyre Therapeutics SYRE Stock Holding History

Thomas Steyer’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-666,000	Closed	-$15.7M	–	177
2024 Q2	$15.7M	Buy	666,000 +200,000	+43%	+$6.75M	0.07%	78
2024 Q1	$17.7M	Buy	+466,000	New	+$13.5M	0.08%	77

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Thomas Steyer's SYRE Position: Q3 2024 in Review

Thomas Steyer sold out of Spyre Therapeutics (SYRE) in Q3 2024, closing a stake of 666,000 shares — an estimated $15.7M sold.

Thomas Steyer first reported a position in SYRE in Q1 2024 and held it in 2 quarters. The position peaked at $17.7M in Q1 2024. 119 funds tracked by Wall St. Rank hold SYRE as of Q3 2024.

Thomas Steyer reported no remaining Spyre Therapeutics position as of Q3 2024 after selling out during the quarter.
Thomas Steyer sold 666,000 Spyre Therapeutics shares in Q3 2024, an estimated $15.7M.
Thomas Steyer first reported a position in Spyre Therapeutics in Q1 2024 and held it in 2 quarters.
Thomas Steyer's Spyre Therapeutics position peaked at $17.7M in Q1 2024.
119 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2024.

Based on Farallon Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.